IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v10y2019i1d10.1038_s41467-019-10993-5.html
   My bibliography  Save this article

Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma

Author

Listed:
  • Jian-Fang Ning

    (Massachusetts General Hospital and Harvard Medical School
    University of Minnesota Medical School)

  • Monica Stanciu

    (Massachusetts Institute of Technology)

  • Melissa R. Humphrey

    (Massachusetts General Hospital and Harvard Medical School)

  • Joshua Gorham

    (Harvard Medical School)

  • Hiroko Wakimoto

    (Harvard Medical School)

  • Reiko Nishihara

    (Brigham’s and Women’s Hospital and Harvard Medical School)

  • Jacqueline Lees

    (Massachusetts Institute of Technology)

  • Lee Zou

    (Massachusetts General Hospital and Harvard Medical School
    Harvard Medical School)

  • Robert L. Martuza

    (Massachusetts General Hospital and Harvard Medical School)

  • Hiroaki Wakimoto

    (Massachusetts General Hospital and Harvard Medical School
    Massachusetts General Hospital and Harvard Medical School)

  • Samuel D. Rabkin

    (Massachusetts General Hospital and Harvard Medical School)

Abstract

PARP inhibitors (PARPis) have clinical efficacy in BRCA-deficient cancers, but not BRCA-intact tumors, including glioblastoma (GBM). We show that MYC or MYCN amplification in patient-derived glioblastoma stem-like cells (GSCs) generates sensitivity to PARPi via Myc-mediated transcriptional repression of CDK18, while most tumors without amplification are not sensitive. In response to PARPi, CDK18 facilitates ATR activation by interacting with ATR and regulating ATR-Rad9/ATR-ETAA1 interactions; thereby promoting homologous recombination (HR) and PARPi resistance. CDK18 knockdown or ATR inhibition in GSCs suppressed HR and conferred PARPi sensitivity, with ATR inhibitors synergizing with PARPis or sensitizing GSCs. ATR inhibitor VE822 combined with PARPi extended survival of mice bearing GSC-derived orthotopic tumors, irrespective of PARPi-sensitivity. These studies identify a role of CDK18 in ATR-regulated HR. We propose that combined blockade of ATR and PARP is an effective strategy for GBM, even for low-Myc GSCs that do not respond to PARPi alone, and potentially other PARPi-refractory tumors.

Suggested Citation

  • Jian-Fang Ning & Monica Stanciu & Melissa R. Humphrey & Joshua Gorham & Hiroko Wakimoto & Reiko Nishihara & Jacqueline Lees & Lee Zou & Robert L. Martuza & Hiroaki Wakimoto & Samuel D. Rabkin, 2019. "Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma," Nature Communications, Nature, vol. 10(1), pages 1-18, December.
    • Handle: RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-10993-5
    DOI: 10.1038/s41467-019-10993-5
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-019-10993-5
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-019-10993-5?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-10993-5. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.